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Abstract
Circulating tumor cells (CTCs) provide a readily accessible source of tumor material from patients with cancer.
Molecular profiling of these rare cells can lead to insight on disease progression and therapeutic strategies. A critical
need exists to isolate CTCs with sufficient quantity and sample integrity to adapt to conventional analytical tech-
niques. We present a microfluidic platform (IsoFlux) that uses flow control and immunomagnetic capture to enhance
CTC isolation. A novel cell retrieval mechanism ensures complete transfer of CTCs into the molecular assay. Im-
proved sensitivity to the capture antigen was demonstrated by spike-in experiments for three cell lines of varying
levels of antigen expression. We obtained spike-in recovery rates of 74%, 75%, and 85% for MDA-MB-231 (low),
PC3 (middle), and SKBR3 (high) cell lines. Recovery using matched enumeration protocols and matched samples
(PC3) yielded 90% and 40% recovery for the IsoFlux and CellSearch systems, respectively. In matched prostate
cancer samples (N = 22), patients presenting more than four CTCs per blood draw were 95% and 36% using IsoFlux
and CellSearch, respectively. An assay for detecting KRAS mutations was described along with data from patients
with colorectal cancer, of which 87% presented CTCs above the assay's limit of detection (four CTCs). The CTC KRAS
mutant rate was 50%, with 46% of patients displaying a CTC KRAS mutational status that differed from the pre-
viously acquired tissue biopsy data. The microfluidic system and mutation assay presented here provide a complete
workflow to track oncogene mutational changes longitudinally with high success rates.
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Introduction
Circulating tumor cells (CTCs) disseminate into the blood from
both primary and metastatic cancers and are believed to play a role
in the spread of the disease throughout the body [1]. There has been
considerable interest in analyzing these cells as a potential source of
clinically actionable information relating to molecular profile of the
patient’s disease. CTCs can be accessed repeatedly and noninvasively
and, thus, provide a clinically feasible methodology for tracking
longitudinal changes in disease profile that is not readily accom-
plished with conventional biopsy approaches.
Numerous approaches have been employed to isolate and use
CTCs for diagnostic and discovery applications. The CellSearch Sys-
tem (Veridex, Raritan, NJ) was cleared by the US Food and Drug
Administration in 2004 as a prognostic test for breast cancer based
on the enumeration of CTCs [2]. This platform uses immunomagnetic
isolation of cells and immunofluorescence detection to count individual
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CTCs. Other platforms have been described in the literature or com-
mercially released using alternative isolation modalities such as size-
based separation, affinity capture, and imaging cytometry [3–5]. A
key limitation of these technologies is the ability to release and re-
cover viable intact CTCs for downstream molecular analysis. Cells
that have been isolated onto antibody-coated microfluidic channels,
porous filters, and glass slides often adhere tightly to their substrate
and, thus, make it difficult to remove these cells for further analysis.
Other limitations such as low cell recovery, low purity, and dimin-
ished viability have contributed to preventing widespread use of
CTCs in the laboratory and clinical environments.
The IsoFlux System (Fluxion Biosciences Inc, South San Francisco,
CA) was designed to address these limitations by providing high-
sensitivity rare cell isolation coupled with a novel cell retrieval mech-
anism. The system uses immunomagnetic beads that facilitate use of
single or multiple capture antibodies to target cells of a specific pathol-
ogy. The sample passes through a microfluidic device that contains an
isolation zone to capture CTCs on the upper surface of the cartridge
in an externally applied magnetic field. The roof of the microfluidic
channel decouples from the rest of the cartridge and transfers off-chip
with the CTCs still retained on its surface, providing near perfect
transfer efficiency. The resulting CTC sample remains suspended in
a droplet of approximately 3 μl that can then be directly recovered
into cell lysis buffer for molecular analysis or onto a microscopy slide
for pathologic analysis. The low volume transfer is particularly well
suited for molecular biology reactions that often have limited vol-
umetric inputs on the order of 10 to 20 μl [6]. This overcomes pre-
vious limitations of other rare cell isolation techniques that often
result in significantly larger volumes on the order of 350 μl to 1 ml
to recover cells [7]. The IsoFlux System enables molecular charac-
terization of intact viable CTCs or isolated DNA, RNA, or protein.
The cells can be processed using techniques well known to the
clinical and molecular biology field, including quantitative polymerase
chain reaction (qPCR), fluorescence in situ hybridization, and next-
generation sequencing.
Here, we present validation of the IsoFlux System and a qPCR
mutational analysis assay for the KRAS gene. KRAS mutations have
a 30% to 40% prevalence in colorectal cancer (CRC) and also appear
in other tumor types such as pancreatic and non–small cell lung
cancers. Presence of a mutation on this gene has been correlated with
poor response to anti–epidermal growth factor receptor (EGFR)
inhibitors such as panitumumab and cetuximab therapy [8]. Analytical
validation was performed using three cancer cell lines spiked into
healthy donor blood. Tumor cell lines that span a range of capture
antigen surface expression to more closely approximate clinical samples
were chosen. Experiments were performed to assess CTC recovery,
sensitivity, linearity, variability, and purity. Cell transferability off-chip
was also assessed to characterize the amount of cellular material that
ends up in the downstream analysis. The mutation detection assay
was characterized analytically using both genomic DNA (gDNA) and
spiked blood samples to assess limits of detection (LODs), specificity,
and sensitivity.
Clinical validation of the CTC to qPCR workflow was performed
using blood samples from patients with CRC, who have had prior
KRAS mutational analysis performed from a tissue biopsy. Interest-
ingly, 46% of the patients had a mutational status on the CTCs that
differed from the previously acquired tissue samples. This highlights
the feasibility of using CTCs to track mutational status changes
longitudinally for a large majority of patients with CRC.
Materials and Methods
Microfluidic Design and Control Instrumentation
The IsoFlux microfluidic cartridge contains three fluidic reservoirs
that are connected by a microfluidic flow path on the bottom of the
device (Figure 1A). The sample is loaded in the inlet and then flows
through an isolation zone where the target cells are collected. The
remaining background cells are collected in a waste well. After the
sample has been passed through the channel, a wash buffer is intro-
duced from the wash well.
The isolation zone is an expanded cavity that extends above the
main flow channel (Figure 1B). The sample flows into this region
at reduced velocities and sees an externally applied magnetic field
from above the collection substrate. Targeted cells with magnetic
beads are attracted to the roof of the isolation zone, whereas
other unbound cells are biased from flow and gravitational forces
to continue down the channel and into the waste well. The roof
of the isolation zone is a polymeric disk that is separate from the con-
struction of the main flow channel. At the conclusion of the sample
processing, the disk decouples from the flow channel along with the
magnet, keeping targeted cells apposed to it. Once the magnet is
removed, the targeted cells can be recovered in a microfuge tube for
downstream processing.
The microfluidic device is controlled with an attending benchtop
instrument and embedded touch screen (Figure 1C ). Fluid flow was
controlled pneumatically from an externally supplied pressure inside
the instrument. Up to four devices can be loaded into the instrument
for parallel sample processing. Once inside the instrument, a pneumatic
interface seals around the fluidic reservoirs contained within the
cartridge. A diaphragm pump and electropneumatic regulator create
a controlled operating pressure of 2 psi. This pressure gets distributed
to the sample reservoirs to initiate flow through the microfluidic
channel. Pressures are turned off and on using a bank of solenoid valves
under microprocessor and embedded software control.
Analytical Blood Samples
Analytical samples were prepared to simulate cancer samples in
experiments that rely on knowing the starting concentration of target
cells. Healthy donor peripheral blood was obtained from a commercial
supplier (AllCells, Emeryville, CA) under Institutional Review Board
(IRB) consent. Blood was drawn into EDTA tubes (Vacutainer; BD,
Franklin Lakes, NJ) and subsequently spiked with one of three cancer
cell lines. MDA-MB-231 (breast cancer cell line), PC3 (prostate can-
cer), and SKBR3 (breast cancer) cells (ATCC, Manassas, VA) were
used for analytical instrument performance validation experiments.
MDA-MB-231 cells were also used for KRAS assay validation because
this line harbors a known heterozygous KRAS G13D mutation. The
cell lines used have been reported to span the range from low to high
epithelial cell adhesion molecule (EpCAM) expression [9–11] and were
selected to represent the variability seen in clinical samples. Cells sus-
pended in a stock solution were first counted on a hemocytometer
and then spiked into 7 ml of whole blood in varying concentrations.
Clinical Blood Samples
For comparative recovery studies, clinical samples were obtained
from 22 patients with prostate cancer (Memorial Sloan-Kettering
Cancer Center, New York, NY) under IRB consent. For qPCR stud-
ies, samples were obtained from 15 patients with metastatic CRC
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(Horizon Oncology Research Inc, Lafayette, IN) under IRB consent.
Two tubes of 7 ml of whole peripheral blood were collected in
EDTA tubes from each patient. Samples processed on the IsoFlux
instrument were shipped overnight at room temperature in an insu-
lated shipping cooler. All clinical samples were processed the next day
within 36 hours of the initial blood draw. Previous studies found
white blood cell (WBC) counts to be unaltered under these condi-
tions for at least 3 days [12]. It is therefore our assumption that sig-
nificant lysis does not occur within 36 hours. In our own experience,
no significant difference in either CTC recovery or WBC back-
grounds has been observed between different storage times ranging
from day of draw (<6 hours) to overnight shipping (24-36 hours).
In the future, careful studies using matched samples are needed to
fully address the effect of EDTA storage time.
All patients with CRC had previously undergone tissue biopsy fol-
lowed by KRAS mutational analysis performed before the blood
draw for CTC isolation.
Sample Preparation
Blood tubes were processed to recover the peripheral blood mono-
nuclear cell fraction. LeucoSep tubes (Greiner Bio-One, Monroe,
NC) were prepared by adding 15 ml of Ficoll-Paque Plus (GE
Healthcare, Pittsburgh, PA). The peripheral blood mononuclear cell
fraction was recovered and resuspended in 1 ml of binding buffer
(CTC Enrichment Kit; Fluxion Biosciences Inc). Immunomagnetic
beads preconjugated with anti-EpCAM antibodies (CTC Enrichment
Kit; Fluxion Biosciences Inc) were added directly to the sample and
incubated for 2 hours at 4°C with passive mixing on a rotator.
CTC Isolation
Following the magnetic bead coupling step, samples were loaded
into the inlet well of the microfluidic cartridge. Samples were flowed
through the channel at a flow rate of 20 μl per minute by applying a
head pressure of 2 psi to the inlet well. Each sample passed through
the channel in less than 45 minutes. After processing, the disk contain-
ing the cells in a hanging drop is inserted into a holder (Figure 1). The
isolated target cells were recovered off the isolation zone disk through
pipetting and dispensed into a microfuge tube for further processing.
Enumeration Analysis
For analytical samples, the spiked cells were prelabeled with Cell-
Tracker Green (Invitrogen, Carlsbad, CA) to provide a more accurate
count of recovered cells. For IsoFlux enumeration, isolated target
cells were recovered from the disk through pipetting and dispensed
Figure 1.Microfluidic design and control instrumentation. (A) The microfluidic device for CTC isolation contains a sample inlet reservoir
that feeds into a microfluidic channel. (B) A schematic depiction of the flow path consisting of two inputs (a sample and a wash buffer
well), isolation region, and waste well. (C) The sample passes through an isolation zone where magnetically labeled cells are captured
on the top of the channel in the presence of a magnet. After processing, the cells are retrieved inside the instrument by lifting the cap
off the channel and securing it to either microfuge tube or holder to remove the target cells through pipetting (not shown). (D) Up to
four microfluidic cartridges can be processed in parallel inside the instrument, which uses pneumatic-driven flow to process the samples.
530 Mutational Analysis of Circulating Tumor Cells Harb et al. Translational Oncology Vol. 6, No. 5, 2013
onto a standard slide for imaging. For matched CellSearch PC3 cell line
spike-in experiments, cells were recovered using the CellSearch Profile
Kit after magnetic separation. Instead of using the CellTracks analysis
module, these cells were dispensed onto a standard slide and imaged
using the same protocol as IsoFlux spike-in recovery experiments.
For clinical samples, immunofluorescence staining was performed
using anti-cytokeratin (CK), anti-CD45, and Hoechst 33342 (nucleus)
(CTC Enumeration Kit; Fluxion Biosciences Inc). Recovered CTCs
were fixed with phosphate-buffered saline (PBS) buffer containing
1.8% formaldehyde, washed, and blocked with 1% goat sera in PBS.
Cells were stained with rabbit polyclonal anti-human CD45 antibody
followed by goat anti-rabbit antibody conjugated with Cy3. After per-
meabilization with 0.1% Triton X-100, cells were then stained with
anti-CK (fluorescein isothiocyanate). For CK staining, we used anti-
body clone CK3-6H5, a pancytokeratin-specific antibody likely to
recognize all simple epithelium CKs; it has been shown to bind CKs
[7,8,13]. Stained CTCs were mounted in SlowFade Gold mount-
ing media with Hoechst 33342 (Life Technologies Inc, Foster City,
CA) to Sensoplate Glass-Bottom Multiwell Plates (Greiner Bio-One)
for imaging.
Cells were scored as CTCs if they were CK+, CD45−, nucleated,
and morphologically intact. The total cell count was determined by
counting all nuclei and reported as a measure of sample purity. Imag-
ing was performed using an inverted epifluorescence motorized
microscope (AxioObserver Z1; Carl Zeiss, Oberkochen, Germany)
and imaging software (BioFlux Montage; Fluxion Biosciences Inc).
For matched CellSearch clinical samples, cells were analyzed using
the same three markers [CK+, CD45−, and 4′,6-diamidino-2-
phenylindole+ (DAPI+)] using the CellTracks System from Veridex.
KRAS Mutational Analysis—CTC Samples
CTCs were pipetted off the recovery disk and dispensed into a
microfuge tube in less than 20 μl of PBS. Cell pellets after PBS
removal were stored at −80°C until processed for mutational analysis.
Samples remained frozen from 2 to 4 months before processing.
Whole-genome amplification was performed directly on recovered cells
after cell lysis (REPLI-g UltraFast Mini Kit; Qiagen, Valencia, CA).
Amplified gDNA was purified and eluted in 50 μl of AE buffer
(QIAamp DNA Micro Kit; Qiagen) and used for qPCR. gDNA
was tested for mutations using a panel of KRAS mutation assays
(nucleotide changes of c.34G>T, c.34G>A, c.34G>C, c.35G>T,
c.35G>A, c.35G>C, and c.38G>A, corresponding to amino acid
changes of G12C, G12S, G12R, G12V, G12D, G12A, and G13D)
using Competitive Allele-Specific TaqMan PCR (castPCR) reagents
on a qPCR instrument (StepOne Plus; Life Technologies Inc) accord-
ing to the manufacturer’s recommended protocol [14]. For each point
mutation, a different primer was used (Catalog Nos: KRAS_517,
G12S; KRAS_518, G12R; KRAS_520, G12V; KRAS_521, G12D;
KRAS_522, G12A; KRAS_527, G13C; KRAS_532, G13D). Each
assay well on a 96-well PCR plate received 1 to 2 μl of amplified gDNA
in 20-μl total volume.
KRAS Mutational Analysis—Biopsy Samples
Two methods were used, as described for each patient in the
patient table: Sanger sequencing and PCR.
Sanger sequencing. DNA sequencing is considered the gold stan-
dard for detection of mutations. This method allows determination
of the order of nucleotides in a target DNA sequence. The Sanger
chain-termination method is commonly used in molecular diagnostic
laboratories. In this method, the incorporation of a chemically mod-
ified nucleotide (dideoxynucleotide) terminates extension of the
DNA strand at the point of incorporation. This results in a mixture
of DNA fragments of various lengths. Each dideoxynucleotide (A, T,
C, or G) is labeled with a different fluorescent dye, allowing their
individual detection. The newly synthesized and labeled DNA frag-
ments are separated by size through capillary gel electrophoresis. The
fluorescence is detected by an automated sequence analyzer (i.e., ABI
3730; Applied Biosystems Inc, Carlsbad, CA), and the order of
nucleotides in the target DNA is depicted as a sequence electro-
pherogram. A KRAS mutation will appear as the presence of both
mutant and wild-type KRAS alleles (two overlapping peaks) at the
particular nucleotide that is mutated. The analytic sensitivity of this
method is reported to be 10% to 30% of mutant KRAS in a back-
ground of wild-type sequence [15].
Polymerase chain reaction. DNA is isolated from the sample,
quantified, and amplified by PCR using primers to exon 2 of the
KRAS gene. PCR products are subjected to single nucleotide primer
extension to detect mutations at codons 12 and 13; primer extension
products are analyzed using gel electrophoresis and fluorescence
detection. False positive or negative results may occur for reasons that
include genetic variants or somatic heterogeneity of the tissue sample.
Statistical Analysis
Data are reported as means ± SEM except where noted.
Results
Analytical CTC Recovery and EpCAM Sensitivity
CTCs appear in very low concentrations in the peripheral blood of
patients with cancer and, as such, must be captured with high effi-
ciency to enable diagnostic testing. Recovery efficiency was tested on
the IsoFlux System using model CTC samples that allow for control
of the starting tumor cell number and EpCAM expression level.
Three model tumor cell lines (MDA-MB-231, PC3, and SKBR3)
were spiked into 7 ml of healthy donor blood. The cell lines were
selected to span a range of EpCAM expression levels from low
(MDA-MB-231 at 2.3× background fluorescence and PC3 at 6×
background fluorescence) to high (SKBR3 at 25× background fluo-
rescence) to approximate clinical conditions while challenging the
binding ability of the capturing antibody [9–11]. Recovery linearity
was measured using the PC3 cell line spiked in at levels from 20 to
300 target cells per 7 ml of blood, in triplicate. For PC3 and MDA-
MB-231 cells, the average recovery percentage across all spike-in
levels was 73% and 81%, respectively, with an SD of 16% and
27% (Figure 2, A and B). Linear fits to PC3 and MDA-MB-231
results yielded R2 values of 0.93 and 0.54 with slopes of 0.75 and
0.74, respectively (75% and 74% of cells captured; Figure 2, C and
D). The fits offer a better approximation of the percent recovery as
opposed to average recovery numbers.
Tumor cell line recovery as a function of EpCAM expression is
summarized in Figure 3. The recovery percentages using the IsoFlux
(Figure 3, filled square markers) are 74%, 75%, and 85% for MDA-
MB-231 (n = 7), PC3 (n = 38), and SKBR3 (n = 8), respectively. For
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PC3 cells, solid triangles represent matched sample results that were
run on either CellSearch (blue) or IsoFlux (red) using exactly the
same cell counting protocols. Matched CellSearch PC3 data showed
a recovery rate of 40%, compared to 80% using the IsoFlux System
(n = 4 samples each). Open circles represent literature data for Cell-
Search spike-in recovery from MDA-MB-231 cells at 12% [10] and
SKBR3 cells at 90% [9].
Sample Transfer Efficiency
Another area of concern for CTC capture technologies is the loss
of sample during the retrieval process. While many platforms can
count the number of CTCs directly on the capture substrate (e.g.,
filter, microfluidic channel, and so on), it remains challenging to
retrieve the CTCs off-chip with high fidelity. The IsoFlux System
uses a low-adherence polymer disk to capture cells and transfer them
with high efficiency to a secondary collection vessel (e.g., microfuge
tube, microscopy slide) for further processing. To characterize this, a
series of spiked samples (PC3 cells) that fell in the range of 40 to
60 cells (N = 12) or 90 to 120 cells (N = 8) per 7 ml of blood were
prepared. After processing each sample on the IsoFlux instrument,
half of the samples were enumerated directly on the recovery disk
and the remaining half were transferred off the disk using the stan-
dard recovery protocol onto microscopy slides. Average recovery
measured directly from the retrieval disk was 75% and 68% for
Figure 2. CTC capture efficiency and linearity using tumor cell lines. Model CTC samples were prepared by spiking PC3 (A) and MDA-
MB-231 (B) cells into tubes of healthy donor blood in concentrations ranging from 20 to 300 total target cells per tube. Average CTC
capture efficiency was 73% and 81% with an overall SD of 16% and 27%, respectively. Standard errors are shown for each spiked
concentration. (B) CTC capture levels varied linearly with spike-in concentration (C and D). R2 values were 0.9 and 0.5 with slopes of
0.75 (75% of cells captured) and 0.74.
Figure 3. Recovery dependence on EpCAM expression. A compar-
ison of recovery rates for three different tumor cell lines is shown.
Mean results using the IsoFlux System are plotted with standard
error bars (solid squares) for three cell lines: MDA-MB-231 (n = 7),
PC3 (n = 38), and SKBR3 (n = 8). Solid triangles represent
matched sample results (n = 4 samples each) that were run on
either CellSearch (blue) or IsoFlux (red) using exactly the same cell
counting protocols. Open circles represent literature data for Cell-
Search spike-in recovery from two of the cell lines studied: MDA-
MB-231 [10] and SKBR3 [9].
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the 40 to 60 cell group and 90 to 120 cell group, respectively.
Average recovery measured from the microscopy slides was 72%
for the 40 to 60 cell group and 64% for the 90 to 120 cell group.
The total cell loss in the recovery process was statistically insignifi-
cant, but percent recovery was 3% to 4% lower on average when
undergoing an additional transfer step (Figure W1).
Clinical CTC Recovery Data (Prostate Cancer Samples)
Matched patient samples were processed using the CellSearch and
IsoFlux platforms to measure the effects of increased sensitivity on
clinical samples. Two blood tubes were processed from each patient
to assess the level of CTCs recovered (Figure 4). For both systems,
CTCs were defined as CK+, CD45−, nucleated, and intact (Figure 7).
In this test group, IsoFlux yielded 21 of 22 patients (95%) with CTC
counts above the mutation assay LOD of four cells; CellSearch yielded
8 of 22 patients (36%) with CTC counts above the four-cell LOD.
Analytical Validation of Mutational Analysis Assay
A qPCR assay was developed to detect a panel of seven clinically
relevant KRAS point mutations. The test uses castPCR mutation
detection assays (Life Technologies Inc). castPCR is a highly spe-
cific and sensitive method for detecting and quantitating rare muta-
tions in a sample that contains large amounts of wild-type gDNA.
The technology combines allele-specific TaqMan qPCR with allele-
specific minor groove binder (MGB) blockers to suppress nonspecific
amplification from wild-type alleles, resulting in better specificity than
traditional allele-specific PCR [14]. Each castPCR assay consists of a
mutant assay and a reference assay. The principle readout of the assay
is the difference in threshold cycles (C t) between the mutant and refer-
ence assays, known as dC t. A mutation detection cutoff is established
by running wild-type control samples and subtracting a safety margin
of 2 C t to differentiate between wild-type sample and sample containing
mutant gDNA.
Figure 4. CTC recovery from matched clinical samples. Matched samples from 22 patients with prostate cancer were used to compare
CTC recovery using the IsoFlux System compared to the CellSearch platform that is also based on immunomagnetic separation. For
concomitantly drawn 7.5 ml of blood samples, counts are presented using the two platforms; in both cases, immunostaining was used
to identify CTCs as cells that are CK+, CD45−, and DAPI+ (nucleated).
Figure 5. KRAS mutation assay LODs using purified gDNA. Varying levels of G13D mutant gDNA were mixed with high wild-type back-
ground (10,000 wild-type cells) and analyzed with a KRAS G13D mutant assay and KRAS reference assay. The C t difference between
KRAS mutant and wild-type assays (dC t) was calculated. KRAS mutation is detected when the dC t is below the cutoff dC t value gen-
erated with pure wild-type gDNA (green line). Samples containing four cell equivalents of mutant gDNA in a background equivalent of
10,000 wild-type cells were consistently detected.
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The KRAS mutation detection assay was first characterized using
titrated amounts of mutant gDNA from an MDA-MB-231 cell line
that harbors a heterozygous KRAS G13D mutation. Varying
amounts of MDA-MB-231 gDNA ranging from 0 to 128 cell equiva-
lents (6 pg gDNA/cell) were added to 60 ng of Jurkat cell gDNA or the
equivalent of 10,000 wild-type cells. A high level of background gDNA
was selected to challenge the assay because this level is 5- to 10-fold
higher than samples typically recovered from the device. Experiments
were performed in triplicate below four copies to resolve the lower
LOD and in duplicate above four copies. The pure wild-type samples
had average dC t values of 23.3 (Figure 4). The mutation detection
cutoff value was set at 21. Samples are determined to contain mutant
if the dC t falls below this cutoff value. The assay was found to reliably
detect mutant down to four copies. Below this level, some samples fell
above the mutation detection cutoff and some fell below, suggesting
that four copies is a good approximation of the assay LOD.
Next, we prepared a set of model CTC samples to assess the
LODs using more realistic conditions and the complete assay work-
flow. The same tumor cell line (MDA-MB-231) was spiked at con-
centrations of 0 to 200 cells into vials of 7 ml of healthy donor blood.
Each spiking concentration was prepared in triplicate and processed
on the IsoFlux System. One sample from each concentration was
enumerated and used to assess cancer cell recovery and background.
The remaining two samples from each concentration were used in
the qPCR mutation assay. Samples containing as few as nine recov-
ered tumor cells were detected on the qPCR mutation assay with a
dC t value around 15, well below the detection cutoff of 21 (Figure 5).
Healthy control samples with no mutant cell spike in had dC t values
Figure 6. Assay LODs using model CTC samples. Varying levels of KRAS G13D mutation–positive tumor cells (MDA-MB-231) were
spiked into healthy donor blood and processed on the IsoFlux System. gDNA was amplified, purified, and tested for KRAS mutations.
The C t difference between KRAS mutant and wild-type assays (dC t) was calculated. Samples having as few as nine recovered tumor
cells were detectable using the qPCR assay. Healthy control samples remained above the mutation detection cutoff.
Table 1. Patient Information, CTC Counts, Tumor Staging, CTC and Biopsy Mutational Status, and Treatment Status of Colorectal Cancer Patients in the Study.
Patient Age/Sex CTC Count Tumor Stage CTC KRAS Status Biopsy KRAS Status/Method Treatment Disease State Total Cell Count Time from Biopsy to
CTC Collection (Days)
1 61/F 16 I G12D Not tested/N/A N/A N/A 2050 N/A
2 64/M 17 IV Wild type Wild type/PCR Avas & Fol/Ava, 5-FU,
Leu/Cli
Stable 1659 2120
3 49/F 93 II Wild type Wild type/Sanger None N/A 12,911 1
4 54/M 600 IV Wild type Wild type/PCR Lav, 5-FU/FOL/Fol,
Erb/Cli/FOL
Progressive 7314 699
5 58/F 7 IV G13D Wild type/Sanger FOL N/A 1129 148
6 71/M 71 IV G12D, G12A G12C/PCR 5-FU N/A 3462 1098
7 73/M 23 IIIB G13D Wild type/Sanger FOL/5-FU, Leu/Fol/FOL/
5-FU, Eu/Cli/5-FU
Progressive (expired) 1389 69
8 59/M 0 IV Wild type Wild type/Sanger FOL, Ava/Fol, Erb/Cli Stable 1148 994
9 67/M 18 IV Wild type Wild type/Sanger Oxa/Cli N/A 5040 337
10 62/M 83 II G13D Wild type/Sanger 5-FU N/A 2484 74
11 69/M 27 II Wild type Wild type/Sanger 5-FU N/A 2213 1076
12 26/F 56 IV Wild type G13D/Sanger FOL, bev/Fol, bev Progressive 1729 223
13 63/M 82 III G13D Wild type/Sanger FOL/Fol/5-FU, Leu/Fol,
Ava/FOL, Ava
Progressive 887 414
14 64/M 0 IV Wild type Wild type/Sanger 5-FU, radiation/FOL/
FOL, Ava
Partial response 924 670
15 75/M 18 IIB G13D Wild type/PCR None N/A 1098 1
Treatments administered: Folfiri (Fol), FOLFOX (FOL), 5-FU, Avastin (Ava), Leucovorin (Leu), bevacizumab (bev), Erbitux (Erb), cetixumab (cet), or clinical trial participation (Cli).
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around 23, which is above the detection cutoff. The results of this
experiment were consistent with the gDNA titration experiments
and confirmed that the complete assay workflow is sensitive down
to single-digit copy levels of mutant DNA.
Clinical Mutational Study of CRC Patient Samples
Clinical evaluation of the KRAS mutation detection assay was per-
formed on 15 patients with CRC. Patients ranged from local (stage I)
disease to metastatic (stage IV) disease (Table 1). Patients had previ-
ously undergone tissue biopsy followed by KRAS mutational analy-
sis. The elapsed time between the primary tissue biopsy and the
blood collection for CTC analysis was 1 to 2120 days (Table 1).
Each patient had two tubes of blood drawn. One was used for enu-
meration, and the other was tested for KRAS mutational status.
One tube of blood was processed from each patient to assess the
level of CTCs and background cells using immunofluorescence
methods previously described. Cells were defined as CTCs if they
were CK+, CD45−, nucleated, and met size and morphologic criteria
(Figure 7). In this test group, 13 of 15 (87%) patients had CTC
counts above the KRAS mutation assay LOD of four cells. The
median CTC count was 25 CTCs. Total nucleated cells were also
measured to assess the level of sample purity. Median total cell count
was 1890 cells, resulting in a median CTC purity of 1.4%.
KRAS mutations were detected in 7 of 15 CTC samples (47%)
from patients with CRC. This level is slightly higher than the
reported frequency of KRAS mutations in primary colorectal tissue
samples [8]. In the cohort that initially tested wild type on the pri-
mary biopsy test, 5 of 11 (45%) of these patients were found to have
an acquired mutation in their CTC samples. These five patients had
between 1 and 414 days elapsed between their primary biopsy col-
lection and CTC blood draw. For the two patients that initially had a
mutation in the primary tissue biopsy, one of them exhibited a dif-
ferent point mutation in their CTC sample (patient 6) and the other
showed wild type in their CTC sample (patient 12). A summary of
results is shown in Figure 8.
Discussion
CTCs provide a potential source of tumor cells that can be analyzed
at the molecular level to help inform patient treatment decisions. A
first generation of devices has been made available to isolate CTCs
for enumeration and other forms of image-based analysis, such as
immunohistochemistry and fluorescence in situ hybridization. There
still remains a significant challenge in recovering sufficient levels of
tumor cell material to exceed the LODs of the available analytical
platforms such as qPCR, digital PCR, and next-generation sequenc-
ing. Obtaining the requisite level of tumor cell material depends on
both the isolation efficiency of the platform and the transfer effi-
ciency of the cells from the device to the downstream analysis. Here,
we present a device for isolation of CTCs that overcomes both of
these limitations.
The IsoFlux System uses immunomagnetic beads to positively iso-
late CTCs based on surface-expressed markers. This approach was
chosen over other methodologies to allow for selection of specific
subgroups of target cells for analysis based on the disease classifica-
tion. While this study employed the use of anti-EpCAM antibodies
for isolation of CTCs still retaining this epithelial marker, other
antibody combinations can readily be used to isolate other types of
CTCs, such as ones undergoing epithelial-to-mesenchymal transition
or for cells displaying stem cell markers. This capability has a distinct
advantage over physical isolation approaches such as size filtration. It
Figure 7. Representative images of CTCs and background WBCs from patients with CRC. CTCs were enumerated using immunofluo-
rescence staining for CK (fluorescein isothiocyanate, green), CD45 (Cy3, red), and nucleus (Hoescht 33342, blue). A CTC is defined as CK+,
CD45−, DAPI+, and morphologically intact.
Figure 8. Summary of colorectal cancer test group.
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has been shown that CTCs have a broad distribution of size, includ-
ing cells that are as small or smaller than WBCs and thus are not
efficiently isolated with a filter of a singular size threshold [11,16].
To characterize CTC recovery efficiency analytically, a number of
groups have performed experiments recovering cancer cell lines of
varying EpCAM expression levels from whole blood [9,10]. While
cell lines do not reproduce in vivo heterogeneity, spike-in experiments
have the advantage of yielding a percent recovery metric for the sys-
tems employed. When characterized using fluorescent EpCAM anti-
body binding (either by microscopy or by flow cytometry), tumor cell
lines present a wide range of EpCAM expression, from about 2× to
50× the signal from non–EpCAM-expressing controls [10,11]. For
ex vivo tumor cells dissociated from primary tumors, the expression
levels are heterogeneous and also span a large range of over an order
of magnitude in terms of EpCAM expression [9].
Much of the analytical data characterizing EpCAM-based CTC
isolation has been obtained on the CellSearch System; thus, we have
compared the IsoFlux System to CellSearch performance as a bench-
mark. An advantage of analytical recovery experiments is the ability
to obtain unambiguous counting results if cells are fluorescently
labeled before the spike-in step, a method we employed in all of
our analytical experiments. CellSearch performs very well for cell
lines that are high EpCAM expressers like SKBR3 and MCF7 (recov-
ery >80%), but the literature consistently reports lower recovery for
lower EpCAM expressers [9,10]. For example, Punnoose et al. report
recovery of >75% for SKBR3 cells, but lower recovery of only 42%
for the lower EpCAM CAL-120 cell line, with a trend to even lower
recovery (25%) when samples were stored for 48 hours [9]. Sieuwerts
et al. report recovery of only 12% for the low expression cell line
MDA-MB-231 and recovery from 30% to 60% for other middle
expression breast cancer cell lines [10]. In this study, we have used
three cell lines that span the range from low to high EpCAM expres-
sion: MDA-MB-231 at 2.3× control, PC3 at 6× control, and SKBR3
at 25× control. Significantly higher recovery of MDA-MB-231 and
PC3 cells (74% and 75%, respectively) for the IsoFlux System indi-
cates a higher sensitivity to EpCAM of this microfluidic immuno-
magnetic approach compared to the bulk immunomagnetic approach
used by the CellSearch System (Figure 3). For PC3 cells that are middle
EpCAM expressers [11], we directly compared the two platforms by
using the IsoFlux System and the CellSearch Profile Kit for extracting
cells and analyzing the samples using the same cell staining protocols,
the same imaging platform, and the same counting methodology. We
believe that identical counting protocols are important in that they
remove any bias due to cell staining, microscopy, or image analysis that
might otherwise occur. That experiment yielded roughly twice the
number of PC3 cells recovered by IsoFlux compared to CellSearch
(90% and 40% recovery, respectively; Figure 3).
The hypothesis that higher system sensitivity to EpCAM leads
to improved CTC recovery is also supported by matched patient
sample data in a prostate cancer cohort (Figure 4). A large number
of patients that presented no CTCs using CellSearch displayed CTCs
above the qPCR assay LOD (four cells) using the IsoFlux micro-
fluidic platform. Ninety-five percent of patients tested with the
IsoFlux Sytem had CTCs above the qPCR LOD compared to 36%
using CellSearch. This greatly improves the successful read rate for
the qPCR assay presented, as at least five CTCs are required for the
mutation detection protocol to yield reliable results. For the samples
enumerated here, CTC identification followed the same definition
employed by the CellSearch System: Tumor cells are defined as being
CK+, CD45−, and DAPI+ (nucleated) by microscopic evaluation.
While these prostate patient sample counts are significantly higher
with respect to previous publications using CellSearch and immuno-
magnetic separation, they are consistent with a recent publication by
Ozkumur et al. using a sensitive microfluidic technology in the re-
search setting [11]. Our colorectal patient cohort showed a similar
CTC count distribution for patients with prostate cancer, with 87%
of patients above the assay LOD of four cells, compared to literature
values of 23% using the CellSearch System [17].
The IsoFlux System has been optimized to maximize recovery of
low EpCAM-expressing cells by varying the microfluidic capture
zone dimensions, the velocity of cells in the capture zones (flow rate),
and magnetic bead coupling reaction. It is difficult to compare this
approach to other bulk immunomagnetic approaches, such as Cell-
Search, because the cartridge dimensions, magnetic forces, bead reagent
magnetic moments, and hydrodynamic forces are not known for
other platforms. However, there are a few important differences of this
microfluidic flow-based approach with respect to bulk immuno-
magnetic separation used in previous CTC recovery reports.
First, flow is used to direct cells across a high magnetic field iso-
lation zone (below 1 mm2) at a known velocity (v = 0.37 mm/s).
This controls both the magnetic force applied to each bead and
the cell’s residence time in the isolation zone and results in improved
capture efficiency (Figure 1). Unlabeled background WBCs only
experience gravitational forces directed toward the bottom of the
channel and hydrodynamic forces due to flow that cause cells to
continue past the isolation zone and into the waste reservoir. This
is different from a bulk (no flow) approach, whereby the entire hold-
ing volume needs to be exposed to the magnetic field gradient. The
microfluidic approach leads to reduced background contamination
and results in a median target cell purity of 1.4% (CTC count/total
cell count × 100%), which is appropriate for the qPCR assay
described. Immunomagnetic CTC recovery in a microscale flow
channel was demonstrated in a recent publication [11], whereby cells
were deflected while passing through a high magnetic field region.
Similar to our results, Ozkumur et al. found improved CTC numbers
from prostate samples compared to CellSearch (62% of patients above
four CTCs) and higher recovery from low EpCAM-expressing cell
lines like PC3 (>85% recovery).
Second, the off-chip recovery is improved by retaining cells on a
collection surface that is decoupled from the flow path and becomes
part of the collection chamber. We have characterized the loss due to
off-chip transfer to be below 5% (Figure W1). In contrast, other
methods rely on removal of the magnetic field and extensive flushing
of the capture cartridge.
Third, the beads used in the IsoFlux System have larger diameter
(4.5 μm) and therefore have a larger magnetic moment compared to
nanoscale particles employed by the CellSearch System. This effec-
tively means that target cells can be isolated with far fewer beads
attached, as the magnetic moment scales with bead volume. This
is likely to contribute to the higher sensitivity, where low antigen
levels are present on the cell surface.
A key development of this platform is the ability to efficiently
transfer CTCs to the downstream analysis. Several CTC isolation
systems that are primarily limited to image-based analysis directly
on the capture device have been reported [9–11,16–21]. It remains
a challenge to isolate CTCs and transfer them in a format that is
optimal for molecular analysis. The key requirements include high
CTC recovery, high viability of the captured cells, minimal back-
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ground contamination, and low elution volume. The removable
isolation zone disk transfers the CTCs off the cartridge in a hanging
droplet of approximately 3 μl. This low-volume droplet can then be
transferred to a recovery tube through pipetting into a 10 to 20 μl of
collection buffer volume that can vary according to the requirements
of the downstream assay. Many state-of-the-art molecular analysis
systems have limited volumetric inputs of sample around 10 to 20 μl
that can be loaded into a single channel or well [19]. Thus, it is impor-
tant to deliver a concentrated sample that fits into the volumetric limits
or there will be some sacrifice to the sensitivity of the platform.
Once the CTC sample is transferred away from the system, there
are many types of biomarker analysis platforms that can offer clini-
cally useful information. Here, we present a qPCR mutation detec-
tion assay that can be applied to identify a large number of known
oncogene mutations. As an example, we interrogated a panel of seven
clinically relevant point mutations on the KRAS gene. KRAS muta-
tions are frequently found in carcinomas such as colorectal, lung, and
pancreatic cancers [20]. Patients identified as having a KRAS muta-
tion have been shown to not respond to EGFR-targeted therapies
such as bevacizumab, cetuximab, and panitumumab [21]. The assay
developed here uses the castPCR mutation detection technology.
castPCR technology combines allele-specific TaqMan qPCR with
allele-specific MGB blockers to suppress nonspecific amplification
from wild-type alleles, resulting in better specificity than traditional
allele-specific PCR, improving the overall sensitivity and specificity
of the assay. The assay was evaluated analytically using titrated
gDNA and shown to detect down to four copies of target DNA in
a background of 10,000 wild-type cells (Figure 5), a background far
exceeding the median background of below 2000 cells observed in
clinical samples. It was also confirmed using spiked cell samples on
the IsoFlux System that mutations could be detected in samples
containing as few as nine target cells (Figure 6). Two separate blood
tubes were used to obtain both enumeration and matched qPCR
data; the development of protocols that can transfer the same
sample from imaging to downstream molecular work is a planned
future development.
Recovering measurable CTCs in a high percentage of patients is an
important factor in establishing the clinical utility of the system. A
recently published study also aimed at determining KRAS status for
patients with CRC using the CellSearch System concluded that
improvements would be needed to extract mutational data from a
majority of patients [17], as only 36% of patients were over a 3 CTC
threshold. This is in agreement with other CRC CellSearch studies
reporting CTC positive (>2) patient fractions of 52.5% and 49%,
respectively [18,22]. In contrast, the IsoFlux System isolated more than
seven CTCs from 87% of patients with CRC in our 15-patient cohort,
which is well above the mutation assay LODs. We measured a 40%
discordance between primary biopsy and CTC status that is comparable
to literature value of 50% reported by Fabri et al. [18]. Mostert et al.
[17] reported 25% discordance between primary tumor and metastatic
sites but had insufficient data to correlate tissue-based KRAS status with
CTCs. Gasch et al. performed single-cell CTC analysis and found
significant heterogeneity within CTCs coming from a single patient
(5 of 15 CTCs were KRASmt). However, they did not report overall
agreement with primary tumor KRAS status.
One of the likely explanations for this is that the patients acquired
the KRAS mutation in the elapsed time between the tissue biopsy
and blood collection for CTC analysis. We did find one patient with
KRASmt primary tissue but KRASwt CTC results; while this is
unusual, it does agree with the results of Mostert et al. [17], wherein
two patients presented CTC counts above their LOD but were CTC
KRASwt despite being KRASmt in tissue samples. This may be due
to tumor heterogeneity, which has been well documented [18]. The
patient disease status (stable vs progressive) and treatment history are
presented in Table 1. There is a statistically significant difference
between the CTC counts of patients with progressive disease, median
of 56 ± 15 (standard error, n = 4), and patients that were either not
categorized, 18 ± 12 (standard error, n = 9), or stable, 8.5 ± 12 (standard
error, n = 2). Average numbers of CTCs detected per patient also
increased with stage: stage I with 16 CTCs (n = 1), stage II with 55 ±
38 (n = 4), stage III with 53 ± 30 (n = 2), and stage IV with 96 ±
73 (n = 8). Patients 2 and 4 had received cetuximab (Erbitux), a
KRAS-dependent EGFR inhibitor, during the course of treatment.
Both were KRASwt by both CTC and primary biopsy tests. Patient 2
is stable, whereas patient 4 has progressive disease. The patients that
acquired CTC KRAS mutations but were KRASwt as per the original
biopsy were all undergoing chemotherapy treatment [Folfiri, FOLFOX,
5-fluorouracil (5-FU)]. Larger studies will be required to determine the
correlation between CTC mutational status and response to anti-EGFR
therapy in a statistically significant way. Further studies are warranted to
track individual patients across multiple time points and to more closely
compare the CTCmutational status to that of the primary andmetastatic
tumors (i.e., by obtaining tissue and blood at the same time point).
The ability to track clinically relevant biomarkers longitudinally is
one of the primary advantages of CTCs as a biomarker. This study
highlights a workflow that allows profiling of CTC mutational status
in the patient population over time for a majority of patients.
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Figure W1. Recovery of CTCs from device to collection vessel.
Target cell loss during the critical recovery step was characterized
to be between 3% and 4% of the total CTC number.
